Kerstin Pfister
YOU?
Author Swipe
View article: The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors
The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors Open
Background Current aftercare in breast cancer survivors aims to detect local recurrences or contralateral disease, while the detection of distant metastases has not been a central focus due to a lack of evidence supporting an effect on ove…
View article: Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer
Is Radiographic Aftercare Obsolete? How Testing Positive for ctDNA Can Be a Precedent for Late Relapse, Even in Low-Risk Hormone-Receptor-Positive Breast Cancer Open
Current aftercare after early breast cancer overlooks recent evidence on circulating free tumor DNA (ctDNA). In this case report, we present a patient with low-risk hormone-receptor-positive breast cancer. ctDNA was first detected using a …
View article: Von der Routine zur Präzisionsmedizin – die Nachsorge beim frühen Mammakarzinom auf dem Prüfstand
Von der Routine zur Präzisionsmedizin – die Nachsorge beim frühen Mammakarzinom auf dem Prüfstand Open
Zusammenfassung Die Nachsorge nach kurativer Therapie des Mammakarzinoms folgt seit Jahrzehnten einem weitgehend unveränderten Standard. Ein routinemäßiges Screening auf Fernmetastasen ist nicht empfohlen, sodass diese nur zufällig oder be…
View article: Neue Antikörper-Wirkstoff-Konjugate in der klinischen Praxis zur Behandlung des metastatischen Brustkrebses: Therapie-Adhärenz, Wirksamkeit und Verträglichkeit – Real-World-Daten aus deutschen Brustkrebszentren
Neue Antikörper-Wirkstoff-Konjugate in der klinischen Praxis zur Behandlung des metastatischen Brustkrebses: Therapie-Adhärenz, Wirksamkeit und Verträglichkeit – Real-World-Daten aus deutschen Brustkrebszentren Open
Zusammenfassung Trastuzumab-Deruxtecan (T-DXd) und Sacituzumab-Govitecan (SG) sind Antikörper-Wirkstoff-Konjugate (ADCs) der 3. Generation, die vor Kurzem zur Behandlung des metastatischen Brustkrebses über mehrere Subtypen hinweg und in v…
View article: Correction: Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib – Which One, How and For Whom?
Correction: Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib – Which One, How and For Whom? Open
[This corrects the article DOI: 10.1055/a-2562-8469.].
View article: Association of CMV status with response to neoadjuvant chemoimmunotherapy in early triple-negative breast cancer
Association of CMV status with response to neoadjuvant chemoimmunotherapy in early triple-negative breast cancer Open
View article: Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib – Which One, How and For Whom?
Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib – Which One, How and For Whom? Open
With around 70000 new cases every year, breast cancer (BC) continues to be the most prevalent form of cancer. Hormone receptor-positive, HER2-negative (HR+/HER2−) BC is the most common type and accounts for around 70% of cases of early BC …
View article: Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer?
Do We Need Anthracyclines for Elderly Patients with Triple-Negative Breast Cancer? Open
Objectives: Triple-negative breast cancer (TNBC) requires chemotherapy-based systemic treatment which is usually anthracycline-based (AB). The cardiotoxicity of AB regimens is especially relevant in the elderly population. Therefore, we re…
View article: The survive study - Liquid biopsy guided surveillance in intermediate- to high-risk early breast cancer
The survive study - Liquid biopsy guided surveillance in intermediate- to high-risk early breast cancer Open
View article: Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers
Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers Open
The third-generation antibody-drug conjugates (ADC), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), recently obtained approval for metastatic breast cancer treatment across various subtypes and therapeutic contexts. This re…
View article: Nachsorge beim Mammakarzinom – endlich Bewegung?
Nachsorge beim Mammakarzinom – endlich Bewegung? Open
Zusammenfassung Die Nachsorge nach der kurativen Primärtherapie ist zentraler Bestandteil für Patient*innen mit Mammakarzinom und ist in der Routine seit vielen Jahren unverändert. Maßnahmen zur Früherkennung von asymptomatischen Fernmetas…
View article: Leveraging web search data in Germany to identify unmet needs of contraceptives on a population-based level: A longitudinal retrospective study
Leveraging web search data in Germany to identify unmet needs of contraceptives on a population-based level: A longitudinal retrospective study Open
Background: There are a variety of possible contraceptives available. While medical advice is an important resource for selecting the individual contraceptive, previous research has shown that the Internet has become an increasingly import…
View article: The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers
The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers Open
The NATALEE study showed a significant benefit in invasive disease-free survival (iDFS) for patients with HR+/HER2− early breast cancer (eBC) at intermediate and high risk of recurrence who were treated with the CDK4/6 inhibitor Ribociclib…
View article: Three‐dimensional model for improvement of endometriosis care (<scp>3D‐E</scp>)
Three‐dimensional model for improvement of endometriosis care (<span>3D‐E</span>) Open
Objective Endometriosis affects approximately 10% of women of reproductive age and leads to significant morbidity and financial burden. Consequently, countries such as France and Germany are formulating strategies to combat endometriosis. …
View article: Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers
Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers Open
Background: Approximately 6% of women with breast cancer carry pathogenic germline variants in predisposition genes such as BRCA1 and BRCA2. Depending on personal and family cancer history, it is therefore recommended to test for hereditar…
View article: Evaluating ChatGPT as an adjunct for the multidisciplinary tumor board decision-making in primary breast cancer cases
Evaluating ChatGPT as an adjunct for the multidisciplinary tumor board decision-making in primary breast cancer cases Open
Background As the available information about breast cancer is growing every day, the decision-making process for the therapy is getting more complex. ChatGPT as a transformer-based language model possesses the ability to write scientific …
View article: Evaluating ChatGPT as an Adjunct for the Multidisciplinary Tumor Board Decision-Making in Primary Breast Cancer Cases
Evaluating ChatGPT as an Adjunct for the Multidisciplinary Tumor Board Decision-Making in Primary Breast Cancer Cases Open
As the available information about breast cancer is growing every day, the decision-making process for the therapy is getting more complex. ChatGPT as a transformer-based language model possesses the ability to write scientific articles an…
View article: Extragenital endometriosis in the differential diagnosis of non-gynecological diseases
Extragenital endometriosis in the differential diagnosis of non-gynecological diseases Open
There is, as yet, no causally directed treatment for chronic endometriosis. The treatment is decided upon individually in discussion with the patient, in consideration of risk factors and after assessment of the benefits and risks. Timely …